Skip to main content

Research Pillars & Platforms

Bridging fundamental mechanistic discoveries to prospective clinical trials for AML.

01 Mechanisms & Immunotherapy

Epigenetic Rewiring & Immune Evasion in AML

Blood 2023; 142(23):2002-2015

Acute Myeloid Leukemia (AML) is characterized by recurrent driver mutations (e.g., TP53) coupled with aberrant epigenetic reprogramming. We focus on dissecting how leukemic blasts exploit histone methylation remodeling to silence intrinsic antigen presentation and the cGAS-STING innate surveillance pathway. We develop novel targeted interventions, such as PLK4 inhibition, to trigger epigenetic-immune reactivation.

  • TP53 Mutation
  • cGAS-STING
  • PLK4 Inhibition
02 Stem Cells & Metabolism

Proton Partitioning, pHi & Metabolic Rewiring

Blood 2022; 139(4):502-522 & Leukemia 2022

Intracellular acid-base homeostasis and carbon flux governance critically dictate hematopoietic stem/progenitor cell fate and leukemogenesis. Building upon pioneering work at Harvard MGH, we demonstrated that proton export alkalinizes intracellular pH to rewire carbon metabolism and fuel progenitor proliferation. We are decoding the precise proton partitioning axes in kinase-activated AML to target metabolic vulnerabilities.

  • Intracellular pHi
  • Carbon Flux
  • Stem-Cell Metabolism
03 Translational Medicine & Trials

Targeted Therapy Resistance & Clinical Translation

Nat Commun 2026; doi:10.1038/s41467-026-71186-5

While tyrosine kinase inhibitors against FLT3-ITD achieve impressive initial responses, secondary resistance invariably leads to fatal relapse. Leveraging our discoveries of resistance axes (e.g., the Tescalcin-NHE1 regulatory axis), our lab translates mechanistic findings into actionable regimens, including a successful Phase II clinical trial evaluating Quizartinib combined with Omacetaxine mepesuccinate.

  • FLT3-ITD
  • Tescalcin-NHE1
  • Phase II Trial

Core Platforms

Three models that carry a mechanism from the bench to a decision.

01 High-Throughput In Vivo

Transgenic Zebrafish Leukemia Models

Utilizing transgenic and fluorescently tagged zebrafish leukemia lines to perform rapid functional genetic validation, high-throughput in vivo chemical screening, and real-time live imaging.

  • High-throughput phenotypic and compound screening on hundreds of embryos daily
  • In vivo dynamic fluorescence tracking of leukemic stem/progenitor niche homing
  • Rapid functional genetics using CRISPR/Cas9 and Tol2 transgenesis
02 Physiological Niche

Patient-Derived Xenografts & Murine Niche

Engrafting primary human leukemic blasts into immunocompromised murine bone marrow niches to faithfully recapitulate clinical clonal heterogeneity, microenvironmental crosstalk, and drug resistance trajectories.

  • Curated primary AML/MDS biobank for precision in vivo transplantation
  • Preclinical evaluation of novel monotherapies and synergistic combinations
  • Multiparametric flow cytometry analysis of bone marrow stromal/immune interactions
03 Multi-Omics & Screening

Single-Cell Multi-Omics & High-Throughput Drug Profiling

Integrating single-cell transcriptomics, epigenomics (ATAC-seq), and stable-isotope tracing metabolomics with high-throughput drug sensitivity profiling on primary blasts to map clonal resistance.

  • Single-cell resolution tracking of epigenetic transitions and metabolic reprogramming
  • Automated 96/384-well primary blast drug screening with synergy quantification
  • Advanced bioinformatics pipeline decoding key driver targets and prognostic biomarkers